GLP-1 drug trial for type 2 diabetes
Part of Hormones & metabolism clinical trials.
This trial tests a new GLP-1 receptor agonist to improve blood sugar control in people with type 2 diabetes. It may be an option if you haven't used a similar drug in the last three months and your medical records are complete.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with type 2 diabetes and not used any study drug like it in the last 3 months.
- You are currently on a diabetes treatment plan that includes experimental drugs.
- Your medical records must have complete information about your health, tests, and medicines.
- You must be willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
This trial tests a new medication called BGM0504 for people with type 2 diabetes that is not well managed with diet and exercise alone. It aims to see if the drug can help lower blood sugar levels.
This trial tests a new once-daily tablet (elecoglipron) against a placebo to see if it can help improve blood sugar control in adults with type 2 diabetes who are already on insulin. It may offer an additional treatment option to help manage your diabetes.
This trial looks at how certain cells in the pancreas work in people newly diagnosed with type 2 diabetes. It may help doctors understand the disease better and find new treatment approaches.
This study tests a combination insulin/GLP-1 medicine (iGlarLixi) with continuous glucose monitoring to see how well it controls blood sugar in Chinese adults with type 2 diabetes. It may help those whose current pills are not working enough.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
Hear when a new T2DM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.